Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. ENTA
ENTA logo

ENTA

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ENTA News

Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme

Dec 26 2025NASDAQ.COM

JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook

Nov 15 2025NASDAQ.COM

Microsoft Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday

Nov 14 2025Benzinga

Enanta Shares Climb Following J.P. Morgan's Overweight Rating on RSV Treatment

Nov 14 2025SeekingAlpha

Enanta Pharmaceuticals Unveils Latest Findings on Zelicapavir and EDP-323, Its N-Protein and L-Protein Inhibitors for Respiratory Syncytial Virus (RSV) Treatment, at IDWeek™ 2025

Oct 20 2025Newsfilter

Enanta Pharmaceuticals Completes Stock Offering

Oct 02 2025Yahoo Finance

Jefferies Boosts Enanta Pharma Rating to Buy and Increases Price Target to $20

Oct 01 2025Benzinga

Major Stock Movers on Wednesday: LAC, NKE, and Others

Oct 01 2025SeekingAlpha

Enanta Pharmaceuticals Reveals Pricing for Increased Public Offering of Common Stock

Oct 01 2025Newsfilter

Enanta Pharmaceuticals Announces $65 Million Common Stock Offering

Oct 01 2025SeekingAlpha

Enanta's RSV Medication Demonstrates Potential to Reduce Recovery Time for High-Risk Adults

Sep 29 2025Benzinga

Enanta's Stock Increases Even After RSV Trial Falls Short of Primary Objective

Sep 29 2025SeekingAlpha

Enanta Pharmaceuticals Announces Encouraging Phase 2b Study Results for Zelicapavir in Treating Respiratory Syncytial Virus (RSV) in High-Risk Adults

Sep 29 2025Newsfilter

Merus Shares Surge 38%; Check Out 20 Stocks Making Moves in Premarket Trading

Sep 29 2025Benzinga

Major Stock Movers on Monday: GSK, MLTX, and Others

Sep 29 2025SeekingAlpha

Biotech Surge on Friday: Clinical Advancements Drive Afternoon Gains

Sep 29 2025NASDAQ.COM